×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SAGE – sage therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SAGE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/28
10:50 pm
sage
SAGE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
Low
Report
SAGE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
3/17
02:10 pm
sage
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
Low
Report
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
3/11
10:12 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $5.00 price target on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $5.00 price target on the stock.
3/4
04:45 pm
sage
Sage Therapeutics Announces R&D Leadership Transition [Yahoo! Finance]
Medium
Report
Sage Therapeutics Announces R&D Leadership Transition [Yahoo! Finance]
3/4
04:15 pm
sage
Sage Therapeutics Announces R&D Leadership Transition
Medium
Report
Sage Therapeutics Announces R&D Leadership Transition
2/25
07:07 pm
sage
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now? [Yahoo! Finance]
Low
Report
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now? [Yahoo! Finance]
2/13
10:56 am
sage
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank [Yahoo! Finance]
Low
Report
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank [Yahoo! Finance]
2/12
02:06 pm
sage
Sage Therapeutics, Inc. Price, Consensus and EPS Surprise [Yahoo! Finance]
Low
Report
Sage Therapeutics, Inc. Price, Consensus and EPS Surprise [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
04:07 pm
sage
Form 4 Sage Therapeutics, Inc. For: Apr 01 Filed by: Quirk Michael C.
Medium
Report
Form 4 Sage Therapeutics, Inc. For: Apr 01 Filed by: Quirk Michael C.
4/2
04:06 pm
sage
Form 3 Sage Therapeutics, Inc. For: Apr 01 Filed by: Quirk Michael C.
Medium
Report
Form 3 Sage Therapeutics, Inc. For: Apr 01 Filed by: Quirk Michael C.
4/1
05:35 pm
sage
Form SCHEDULE 13G Sage Therapeutics, Inc. Filed by: Madison Avenue Partners, LP
Low
Report
Form SCHEDULE 13G Sage Therapeutics, Inc. Filed by: Madison Avenue Partners, LP
3/26
04:37 pm
sage
Form 4 Sage Therapeutics, Inc. For: Mar 24 Filed by: Shiferman Gregory L.
Low
Report
Form 4 Sage Therapeutics, Inc. For: Mar 24 Filed by: Shiferman Gregory L.
3/7
10:01 am
sage
Form SCHEDULE 13G/A Sage Therapeutics, Inc. Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A Sage Therapeutics, Inc. Filed by: FMR LLC
3/6
04:47 pm
sage
Form SCHEDULE 13G/A Sage Therapeutics, Inc. Filed by: MORGAN STANLEY
Low
Report
Form SCHEDULE 13G/A Sage Therapeutics, Inc. Filed by: MORGAN STANLEY
3/4
04:46 pm
sage
Form 8-K Sage Therapeutics, Inc. For: Mar 03
Medium
Report
Form 8-K Sage Therapeutics, Inc. For: Mar 03
2/25
04:55 pm
sage
Form 4 Sage Therapeutics, Inc. For: Feb 24 Filed by: Shiferman Gregory L.
Low
Report
Form 4 Sage Therapeutics, Inc. For: Feb 24 Filed by: Shiferman Gregory L.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/29
SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
13.5%
3/13 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.8%
4/3 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9.3%
12/10 Form 4 Sage Therapeutics, Inc. For: Dec 09 Filed by: IGUCHI KIMI 9.2%
4/19 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. 8.7%
12/5 Sage's oral depression therapy fails in late-stage trial; shares plunge [Reuters (UK)] 8.5%
12/5 SAGE Therapeutics Inc (NASDAQ: SAGE) had its price target lowered by analysts at Guggenheim from $200.00 to $110.00. They now have a "buy" rating on the stock. 7.1%
12/11 Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha] 5.8%
6/27 Sage Therapeutics to Host “Sage FutureCast” Webcast 5.4%
11/1 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.1%
3/13 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.8%
4/3 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9.3%
12/10 Form 4 Sage Therapeutics, Inc. For: Dec 09 Filed by: IGUCHI KIMI 9.2%
4/19 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. 8.7%
12/5 Sage's oral depression therapy fails in late-stage trial; shares plunge [Reuters (UK)] 8.5%
12/5 SAGE Therapeutics Inc (NASDAQ: SAGE) had its price target lowered by analysts at Guggenheim from $200.00 to $110.00. They now have a "buy" rating on the stock. 7.1%
12/11 Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha] 5.8%
6/27 Sage Therapeutics to Host “Sage FutureCast” Webcast 5.4%
11/1 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.1%
TOP News Decliners
12/5
Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? [Yahoo! Finance News]
-59.7%
3/11 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $58.00 price target on the stock. -19.3%
2/27 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $69.00 price target on the stock. -17.4%
3/18 SAGE Therapeutics Inc (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. -12.5%
2/27 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud -12.1%
8/30 Tocqueville Opportunity Is One Of The Best Mid-Cap Funds This Year [Forbes] -6.3%
12/16 Sage: In Need Of Authentic Smudging [Seeking Alpha] -6.0%
3/20 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.4%
3/5 SAGE Therapeutics Inc (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.1%
3/4 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.9%
3/11 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $58.00 price target on the stock. -19.3%
2/27 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $69.00 price target on the stock. -17.4%
3/18 SAGE Therapeutics Inc (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. -12.5%
2/27 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud -12.1%
8/30 Tocqueville Opportunity Is One Of The Best Mid-Cap Funds This Year [Forbes] -6.3%
12/16 Sage: In Need Of Authentic Smudging [Seeking Alpha] -6.0%
3/20 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.4%
3/5 SAGE Therapeutics Inc (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.1%
3/4 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: